Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Ultragenyx Pharmaceutical Inc. RARE

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.


Recent & Breaking News (NDAQ:RARE)

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire November 2, 2021

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire October 26, 2021

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

GlobeNewswire October 25, 2021

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

GlobeNewswire October 18, 2021

GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

GlobeNewswire October 7, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2021

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

GlobeNewswire October 1, 2021

Ultragenyx Announces Crysvita® (burosumab) and UX143 (setrusumab) Data Presentations at Upcoming American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

GlobeNewswire September 27, 2021

GeneTx and Ultragenyx Announce FDA has Removed Clinical Hold on Phase 1/2 Clinical Study of GTX-102 for the Treatment of Angelman Syndrome in the U.S.

GlobeNewswire September 27, 2021

Ultragenyx to Present at Morgan Stanley Healthcare Conference

GlobeNewswire September 7, 2021

MEDIA ADVISORY: Ultragenyx Canada Announces Health Canada Approval of a Second Indication for Crysvita(TM) (Burosumab Injection) for the Treatment of Tumour Induced Osteomalacia in Adults

GlobeNewswire September 7, 2021

Ultragenyx to Participate in Panel at Citi's 16th Annual BioPharma Healthcare Conference

GlobeNewswire September 1, 2021

Ultragenyx Announces Approval of Dojolvi® (triheptanoin) in Brazil for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Adults and Children

GlobeNewswire August 23, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 17, 2021

Ultragenyx to Participate in Gene Therapy Panel at Wedbush PacGrow Healthcare Conference

GlobeNewswire August 4, 2021

Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update

GlobeNewswire August 2, 2021

Ultragenyx to Host Conference Call for Second Quarter 2021 Financial Results and Corporate Update

GlobeNewswire July 27, 2021

Ultragenyx Receives Orphan Drug Designation from FDA and European Commission for UX053, an Investigational mRNA-therapy for the Treatment of Glycogen Storage Disease Type III

GlobeNewswire July 27, 2021

Ultragenyx Appoints Corsee Sanders, Ph.D., to Board of Directors

GlobeNewswire June 30, 2021

GeneTx and Ultragenyx Receive Approval from U.K. Regulatory Agency to Begin Clinical Study of GTX-102 for the Treatment of Angelman Syndrome

GlobeNewswire June 10, 2021